A one-minute look at managed care news during the week of April 27, 2015, including more good news for the much-anticipated PCSK9 inhibitors and growth in the individual insurance market enrollment.
This week, a meta-analysis in JAMA confirmed that the PCSK9 inhibitors dramatically reduce low-density lipoprotein as well as all-cause mortality and cardiovascular mortality. However, an accompanying editorial cautioned against too much enthusiasm.
A new report from the Kaiser Family Foundation found that enrollment in the individual insurance market grew in 2014 after the first open enrollment period of the Affordable Care Act. Enrollment is expected to continue to grow in 2015, but at a slower pace.
The first videos from the Spring 2015 Oncology Stakeholders Summit is now available online here.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More